...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Business of Biosimilars - 14th Annual Conference (October 15-17, 2013 - Boston, Massachusetts, USA)
【24h】

Business of Biosimilars - 14th Annual Conference (October 15-17, 2013 - Boston, Massachusetts, USA)

机译:生物仿制药业务-第14届年会(2013年10月15日至17日-美国马萨诸塞州波士顿)

获取原文
获取原文并翻译 | 示例
           

摘要

Competition in the biological market offers a new set of opportunities and challenges within the healthcare industry. Biosimilars, like generic small-molecule drugs, can provide cost savings and increase patient access, while also promoting innovation. While large molecule manufacturers face many challenges unique to complex therapeutics, it is becoming clear that the commercialization of biosimilars shares many of the same hurdles as the generics market. The 14th Annual Business of Biosimilars Conference provided quality presentations from industry leaders regarding many commercial considerations for stakeholders interested in entering the biosimilars market. Opportunities to network with industry experts were offered, with over 120 attendees.
机译:生物市场的竞争为医疗保健行业带来了一系列新的机遇和挑战。生物仿制药,像通用的小分子药物一样,可以节省成本,增加患者使用率,同时也可以促进创新。尽管大分子制造商面临着复杂疗法独有的许多挑战,但越来越明显的是,生物仿制药的商业化与仿制药市场存在许多相同的障碍。第14届年度生物仿制药业务会议为有兴趣进入生物仿制药市场的利益相关者提供了业界领袖关于许多商业考虑的高质量演讲。提供了与行业专家进行交流的机会,有120多名与会者。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号